Ro integrates with manufacturer distribution

Ro is turning branded GLP-1 access into a software and care coordination business, not a pharmacy margin business. Instead of buying drug inventory and fighting Novo Nordisk or Eli Lilly for the customer, Ro keeps the patient on its own intake, clinician review, lab, messaging, and refill workflow, then routes the prescription into manufacturer backed channels like LillyDirect and NovoCare behind the scenes. That lets Ro keep the front door while offloading supply risk and much of the regulatory burden.1 2

• This became necessary after compounded GLP-1 supply tightened in early 2025. As the FDA crackdown made low cost compounded semaglutide harder to use, Ro shifted branded demand into LillyDirect and NovoCare, with over 50% of its GLP-1 business flowing through those channels by mid-2025.1
• The economics change. On compounded drugs, telehealth players could capture very high fulfillment margins. In manufacturer programs, the drug revenue mostly passes through to pharma, so Ro has to make its money on subscription care, dose titration, labs, adherence support, and the convenience of one Ro branded experience.1 2
• This also sets Ro apart from weight loss apps like Noom and from GLP-1 wrappers like AIOS. Noom differentiates with coaching and tracking around a narrower weight loss product, while AIOS has pushed deeper into pharmacy ownership and at cost branded supply. Ro sits in the middle, with a broad telehealth stack but increasingly manufacturer linked fulfillment.2 3

The next step is for Ro to prove that its layer matters even when drug makers can sell more directly. If manufacturer channels keep expanding, the winners in telehealth will be the companies that own patient onboarding, ongoing monitoring, and employer facing obesity programs, because that is the part pharma does not run well on its own.1 4